入院血浆凝溶胶蛋白低浓度可识别社区获得性肺炎高危患者
该研究在455例因社区获得性肺炎(CAP)住院的成人中检测入院血浆凝溶胶蛋白(pGSN)浓度,并按住院期间最高临床严重程度分为四级结局。结果显示pGSN越低,结局越严重:死亡者中位数25.7 μg/mL,低于普通病房患者的40.3 μg/mL(P = .0001);最低四分位组需有创呼吸或血管活性药物支持及死亡比例均更高。
要点
- 入院pGSN越低,CAP患者住院期间临床结局越严重(P = .0001)。
- pGSN≤32.1 μg/mL者需有创呼吸或升压支持比例更高(21.2% vs 11.7%)。
- pGSN最低四分位组死亡比例更高(8.8% vs 0.9%,P < .0001)。
核心结论
- 在因CAP住院的成人中,入院pGSN浓度越低,住院期间临床结局越严重。
研究设计与样本
- 研究纳入455例因CAP住院的成人,采用酶联免疫吸附试验检测入院pGSN浓度。
- 按住院期间最高临床严重程度分为四级互斥类别:普通病房无ICU、ICU无IRVS或死亡、IRVS无死亡、死亡。
- 比较各级别间入院pGSN浓度,并比较最低四分位组与上三个四分位组的结局。
主要发现
- 总体pGSN中位数(四分位距)为38.1(32.1,45.7)μg/mL。
- 不同严重程度结局间pGSN浓度存在差异(P = .0001):普通病房40.3 μg/mL、ICU 36.7 μg/mL、IRVS 36.5 μg/mL、死亡25.7 μg/mL。
- 最低四分位组(pGSN ≤ 32.1 μg/mL)较上三个四分位组更常需要IRVS(21.2% vs 11.7%,P = .0114)。
- 最低四分位组死亡比例更高(8.8% vs 0.9%,P < .0001)。
关键数值与推荐
- 入院pGSN浓度采用酶联免疫吸附试验测定。
- pGSN最低四分位阈值≤32.1 μg/mL。
- 结局分类基于住院期间最高严重程度:普通病房、ICU、IRVS、死亡。
临床怎么用
- 对CAP住院患者,入院低pGSN可能有助于早期识别高危人群并加强监测。
- pGSN≤32.1 μg/mL者需更关注IRVS与死亡风险。
- 目前pGSN尚属研究性指标,重组人pGSN的疗效尚待未来研究验证。
局限性
- 摘要未报告研究设计类型(如队列或病例对照)及随访细节。
- 摘要未报告多变量校正后的效应量及预测性能指标。
- 摘要未报告单中心或多中心及人群代表性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma gelsolin (pGSN) is an abundant circulating protein that neutralizes actin exposed by damaged cells, modulates inflammatory responses, and enhances alveolar macrophage antimicrobial activity. We investigated whether adults with low pGSN at hospital admission for community-acquired pneumonia (CAP) were at high risk for severe outcomes. METHODS: Admission pGSN concentrations in 455 adults hospitalized with CAP were measured using enzyme-linked immunosorbent assay. Patients were grouped into the following 4 hierarchical, mutually exclusive categories based on maximum clinical severity experienced during their hospitalization: general floor care without intensive care unit (ICU) admission, invasive respiratory or vasopressor support (IRVS), or death; ICU care without IRVS or death; IRVS without death; or death. Admission pGSN concentrations were compared across these discrete outcome categories. Additionally, outcomes among patients in the lowest quartile of pGSN concentration were compared to those in the upper 3 quartiles. RESULTS: Overall, median (interquartile range) pGSN concentration was 38.1 (32.1, 45.7) μg/mL. Patients with more severe outcomes had lower pGSN concentrations (P = .0001); median values were 40.3 μg/mL for floor patients, 36.7 μg/mL for ICU patients, 36.5 μg/mL for patients receiving IRVS, and 25.7 μg/mL for patients who died. Compared to patients with higher pGSN concentrations, patients in the lowest quartile (pGSN ≤ 32.1 μg/mL) more often required IRVS (21.2% vs 11.7%, P = .0114) and died (8.8% vs 0.9%, P < .0001). CONCLUSIONS: Among adults hospitalized with CAP, lower pGSN concentrations were associated with more severe clinical outcomes. Future studies are planned to investigate possible therapeutic benefits of recombinant human pGSN in this population.
引用
- Self WH, Wunderink RG, DiNubile MJ, et al. Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes. Clin Infect Dis. 2019. PMID: 30561561. doi:10.1093/cid/ciy1049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。